Torrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment for Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. Under the agreement, Torrent gains semi-exclusive rights to market as VORXAR while Zydus continues marketing as Lipaglyn and Bilypsa. Licensing fees and milestone payments are part of the pact.